

Press Release

29 April 2013

bioCSL Awarded Major Vaccine Distribution Contracts

bioCSL has been selected by New South Wales Health (NSW Health) and the Western Australian Department of Health (WA DoH) to provide storage and distribution services for government funded vaccine programs. The contracts, awarded after separate tender processes, have a combined value of \$6.8 million.

Under a three year agreement with WA DoH, bioCSL's contract logistics business will manage the storage and distribution of over one million vaccines per year, distributing to 528 metropolitan and 297 regional immunisation service providers.

bioCSL's appointment of a two year contract with NSW Health includes approximately 50,000 deliveries of vaccines each year to over 5,000 private and public immunisation service providers.

These vaccines encompass those covered under the National Immunisation Program (NIP) and additional vaccines for outbreaks and public health response measures.

Operating since 1992, bioCSL has national warehouses and offices spanning five states and provides third party logistics services to both government and commercial enterprises.

bioCSL's Vice President of Operations, Stephen Marlow, says the Company is committed to providing logistics services for this important component of health service delivery.

"bioCSL is pleased to be able to support the secure supply of important vaccines under the National Immunisation Program, helping protect the health and wellbeing of Australians," said Mr Marlow.

---- End ----

Contact

Sharon McHale
Senior Director Public Affairs
CSL Limited

Phone: +613 9389 1506
Mobile: +61 409 978 314
Email: sharon.mchale@csl.com.au
45 Poplar Rd, Parkville
Victoria 3052 Australia

About bioCSL

In Australia and New Zealand, bioCSL markets a comprehensive range of vaccines and pharmaceutical products. bioCSL manufactures, markets and distributes seasonal and pandemic influenza vaccine worldwide. It also manufactures products of national significance for Australia, including antivenoms and Q-Fever vaccine, and supplies diagnostic reagents in the Australasia region. bioCSL's cold-chain logistics business provides services for bioCSL and CSL Behring products, as well as commercial and government customers across Australia.

bioCSL is part of the CSL Group which is headquartered in Melbourne Australia. The CSL Group includes CSL Behring, CSL Plasma and bioCSL and has major facilities in Australia, Germany, Switzerland and the US, with over 11,000 employees working in more than 25 countries.

Visit www.biocsl.com.au for more information.